ChemoCentryx Inc (CCXI)

7.18
0.52 6.80
NASDAQ : Health Care
Prev Close 7.70
Open 7.62
Day Low/High 7.08 / 7.75
52 Wk Low/High 1.92 / 8.78
Volume 40.15K
Avg Volume 145.00K
Exchange NASDAQ
Shares Outstanding 48.15M
Market Cap 356.33M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer

ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer

Company Reports at ASCO 2017 Gastrointestinal Cancers Symposium 24 Week Progression-Free Survival and 48 Week Overall Survival Data as it Continues to Follow Progress in Study Patients

ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016

ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016

Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation

ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer

ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer

Company expects additional data including progression-free survival by the end of 2016

First Week of CCXI February 2017 Options Trading

First Week of CCXI February 2017 Options Trading

Investors in ChemoCentryx, Inc. saw new options become available this week, for the February 2017 expiration.

ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis

ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis

PRIME designation designed to provide path to expedite clinical development and accelerate marketing authorization applications

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting

ChemoCentryx Announces Data Presentation Of Novel CCR6 Inhibitors At The 2016 Society For Investigative Dermatology (SID) Annual Meeting

Psoriasis Treatment via Inhibition of Chemokine Receptor CCR6 Supported by In Vivo Model Data